SCHEMBL3789124

SCHEMBL3789124

CS(=O)(=O)Nc1cccc(NS(C)(=O)=O)c1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 3/20 0.59
NFE2L2 Q16236 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.52
NR3C1 P04150 3/20 0.50
GLO1 Q04760 2/20 0.50
HTT P42858 2/20 0.50
PGR P06401 2/20 0.50
NR3C2 P08235 2/20 0.50
AR P10275 2/20 0.50
ALOX15 P16050 1/20 0.50
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 3/20 0.45
HPGD P15428 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11238658 0.90 KEAP1 (0.53) KEAP1NFE2L2L3MBTL1NR3C1GLO1
SCHEMBL21931409 0.86 KEAP1 (0.50) KEAP1NFE2L2L3MBTL1NR3C1GLO1
SCHEMBL5313202 0.86 KEAP1 (0.50) KEAP1NFE2L2L3MBTL1NR3C1GLO1
SCHEMBL4090066 0.86 KEAP1 (0.50) KEAP1NFE2L2L3MBTL1NR3C1GLO1
SCHEMBL3529403 0.82 KMT2A (0.55) KEAP1NFE2L2HTTPGRAR
SCHEMBL13602477 0.82 ALDH1A1 (0.54) KEAP1NFE2L2NR3C1HTTKMT2A
SCHEMBL13690065 0.80 KMT2A (0.46) KEAP1NFE2L2L3MBTL1NR3C1GLO1
SCHEMBL2068498 0.80 KEAP1 (0.65) KEAP1NFE2L2L3MBTL1NR3C1GLO1
SCHEMBL29904739 0.80 KEAP1 (0.65) KEAP1NFE2L2L3MBTL1NR3C1GLO1
SCHEMBL2318350 0.80 PTGS1 (0.61) KEAP1NFE2L2L3MBTL1NR3C1GLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 KEAP1 1245/4885NFE2L2 1287/4885L3MBTL1 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.